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Carbo/Gem in advanced st IIIb /IV lung cancer, is it really better?
Keren--Rosenberg, Shoshana P.1 Sinatzky, Ekaterina1 Rabkin, Anna1 
Leviov, Michelle1 Shklar, Zoya2 Steiner, Mariana1 
1 Dept. of Oncology Lin Medical Center, Haifa, Israel 2 Dept. of Medi-
cal Oncology, Haifa, Israel 
Between 2002 and 2005 75 pts with NSCLC were treated with carbo-
platin / gemzar, Protocol given consisted of carbo. at AUC 5 on D 1 
and gem. 1000 mg/m2 on D 1 and 8 Q3 weeks.
There were 55 male and 20 female pts, their age ranged from 36 to 84 
years (med 71 ), 
The PS was I in 53 ( 70 .6% ) and II in 22( 29.4%) pts.
27 (36%) pts had stage IIIb disease and 48 (64%) pts had st IV or 
recurrent disease.
Treatment intent was neo - adjuvant in 8 (10.6%) pts and palliative in 
67 (80.4% ) pts.
Cycles received ranged from 1-15 ( med 5 ) percentage given ranged 
from 50 - 100% ( med 80% ).
Myelotoxicity gr III/IV was observed in 35(46.6%) pts and consisted 
mainly in anemia and thrombocytopenia, non hematologic toxicity gr 
III/IV was observed in 8 (10.6%) and consisted mainly in fatigue.
Results: 14 ( 19.7% ) pts were not evaluable for response, PR was 
achieved in 21 (29.5%) pts., MR/SD in 16 (22.5%)pts, NR(no re-
sponse) in 20 (28.1%) pts.
Treatment was stopped in 43 (58.9%) pts due to maximal response, in 
12 ((16.4%) pts due to toxicity and in 18 ( 24.6% )due to other reasons.
Quality of life improved in 12( 7.3%), worsened in 42( 60.8%) and did 
not change in 15( 19%) pts. 
After completion of treatment 1 pt underwent surgery, 7 (9.5% ) pts had 
radiotherapy, 39 ( 53.4% ) pts received a second line treatment and 26 
(35 .6) had supportive care.
At a med. follow up of 10.9 months ( range 0.87 - 41.6 )23 (30.65% ) 
pts. are alive with disease, 51 (68% ) pts are dead of disease.
Kaplan -Mayer survival curves did not show differences among pts. in 
regards with gender or age (below and above 70 ).
Conclusion: This small size retrospective analysis reﬂects other well 
established responses to carbo /gem combination.
Although no formal Quality of life questionnaire were used, striking is 
the fact that according to pts report, quality of life and general well be-
ing worsened in about 70%! This is some-what disappointing in terms 
of real beneﬁt vs toxicity and new more efﬁcient and less toxic drugs 
are desired.
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Gemcitabine - Cisplatin (GC) doublet chemotherapy in the first 
line treatment of the patients (Pts) with advanced non- small cell 
lung cancer (NSCLC): A phase II study
Reza, Salim1 Chowdhury, Qamruzzaman2 Hai, Abdul1 
1 Ahsania Mission Cancer Hospital, Dhaka, Bangladesh 2 National 
Institute of Cancer Research & Hospital, Dhaka, Bangladesh 
Background: Lung Cancer is the leading cause of cancer- related death 
in many countries. NSCLC accounts for about 80% of all lung cancers. 
Despite the progress in imaging and diagnostic procedures, NSCLC 
usually presents as advanced (locally or more frequently disseminated), 
and a small part (around 30%) has to be considered early stage. The ba-
sic treatment of advanced lung cancer is platinum based chemotherapy. 
This phase II study was designed to evaluate the efﬁcacy and safety of 
GC in Pts with advanced NSCLC. 
Methods: From January 2002 to December 2005, 36 Pts with; histo-
logically/ cytologically proven, bidimensionally measurable advanced 
NSCLC, age 18 ~ 75 years with ECOG performance status 0~ 3, no 
prior chemotherapy, life expectancy > 3 months, adequate bone mar-
row, renal, hepatic and haematological values were enrolled. It was 
an open - labeled, non- randomized, single- centered and prospective 
study. The treatment protocol was inj. Gemcitabine 1000 mg/m2 on 
day 1 & day 8 and inj. Cisplatin 75 mg/m2 on day 1 at an interval of 3 
weeks. The efﬁcacy was measured by responses rates and safety was 
measured by adverse events and laboratory blood values. 
Results: This study consisted of 32 (88.89%) male and 4 (11.11%) fe-
male pts. Median age was 55 years. On the Histopathological varieties: 
25 (69.44%) Squamous cell carcinoma, 7 (19.44%) Adenocarcinoma 
and 4 (11.12%) large cell carcinoma were reported. In total, 204 cycles 
chemotherapy were administered with a median of 5.66 cycles per pt 
and 32/ 36 pts were evaluated for responses. The overall response was 
17 (53.12%) with 1 complete and 16 partial responses. 8 (25%) pts 
had stable diseases and 7 (21.88%) had progressive diseases. Overall 
survival was 10.5 months. Grade 3 haematological toxicities were 
observed as follows: neutropenia 32%, anaemia 20% and thrombocyto-
penia 6%. Some non- haematological toxicities including nausea 40%, 
vomiting 25%, mucositis 18%, diarrhoea 20% and peripheral neuropa-
thy 10% were observed. No febrile neurtropenia and fatal events were 
recorded. 
Conclusions: This phase II study supports the use of GC doublet 
combination in chemo naive pts with advanced NSCLC due to its very 
promising anti- tumor activity with well - tolerated toxicities. 
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Pemetrexed single agent chemotherapy in previously treated 
patients with locally advanced or metastatic non-small cell lung 
cancer
Russo, Francesca1 Bearz, Alessandra2 Pampaloni, Gianni1 
1 Eli Lilly Italia, Sesto Fiorentino, Italy 2 Oncologia Medica, Centro di 
Riferimento Oncologico, Aviano, Italy 
Background: The main objective of this study was to evaluate the 
safety of second-line pemetrexed in Stage IIIB or IV NSCLC. 
Methods: Overall, 95 patients received pemetrexed 500 mg/m2 i.v. 
over Day 1 of a 21-day cycle. Patients also received oral dexametha-
sone, oral folic acid and i.m. vitamin B12 supplementation to reduce 
toxicity. NCI CTC 2.0 was used to rate toxicity. All the adverse events 
were graded in terms of severity and relation to study treatment. Dose 
was reduced in case of toxicity and treatment was delayed for up to 42 
days from Day 1 of any cycle to allow recovering from study drug-
related toxicities.Tumor response was measured using the RECIST 
criteria. 
Results: Patients received a median number of 4 cycles and 97.8% of 
the planned dose. Overall, 75 patients (78.9% of treated) reported at 
least one adverse event: 34 (35.8%) had grade 3 as worst grade and 
only 5 (5.2%) had grade 4. Drug-related events occurred in 57.9% 
of patients. Neutropenia (8.4%) and leukopenia (6.3 %) were the 
most common grade 3/4 hematological toxicities. Grade 3 anemia 
and thrombocytopenia were reported in 3.2% and 2.1% of patients, 
